RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Measures of human immunodeficiency virus (HIV) community viral load and HIV incidence among people who inject drugs
Glasheen, C., Johnson, E. O., Lorvick, J., & Kral, A. H. (2018). Measures of human immunodeficiency virus (HIV) community viral load and HIV incidence among people who inject drugs. Annals of Epidemiology, 28(1), 8-12. https://doi.org/10.1016/j.annepidem.2017.10.015
Purpose: To evaluate the measures of community human immunodeficiency virus (HIV) viral load (VL) and the association with HIV incidence among people who inject drugs (PWID).Methods: Data were from 1986 to 1999 Urban Health Study conducted among PWID in the San Francisco Bay Area. Extant measures of community VL use mean VL among HIV + study participants, not accounting for the proportion of HIV- individuals. We compared the strength of the associations between HIV incidence and the traditionally measured mean community VL and a new prevalence-adjusted community VL, calculated by dividing the sum of VL among HIV + participants by the total participants irrespective of HIV status.Results: Mean community VL was not correlated with HIV incidence in this sample of PWID (r(s) = 0.32, P = .28). However, prevalence-adjusted community VL was strongly correlated with HIV incidence (r(s) = 0.69, P = .009). Nested complimentary log-log linear models indicated that increases in community VL and prevalence-adjusted community VL were both associated with HIV incidence, but prevalence adjusted community VL was a more sensitive measure (hazard ratio = 1.28, P = .038 and hazard ratio = 3.29, P < .001, respectively).Conclusions: The effect of community VL on HIV incidence may be stronger than previously reported. Future studies of community VL surveillance should consider accounting for the prevalence of HIV using a prevalence-adjusted community VL measure. (C) 2017 Elsevier Inc. All rights reserved.